Browse

Seronegative spondyloarthropathy--studies from the Asia Pacific region

DC Field Value Language
dc.contributor.authorHowe, Hwee Siew-
dc.contributor.authorZhao, Like-
dc.contributor.authorSong, Yeong Wook-
dc.contributor.authorSpringer, Lauren-
dc.contributor.authorEdmonds, John-
dc.contributor.authorGu, Jieruo-
dc.contributor.authorYu, David T Y-
dc.date.accessioned2010-01-12T06:48:15Z-
dc.date.available2010-01-12T06:48:15Z-
dc.date.issued2007-03-17-
dc.identifier.citationAnn Acad Med Singapore. 2007 Feb;36(2):135-41.en
dc.identifier.issn0304-4602 (Print)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17364081-
dc.identifier.urihttps://hdl.handle.net/10371/29740-
dc.description.abstractRecent therapeutic advances, in particular the use of anti-tumour necrosis factor (anti-TNF) agents, have revived interest in the seronegative spondyloarthropathies (SpA), a group of arthritides characterised by axial skeletal involvement and the absence of rheumatoid factor. The purpose of this article is to review the studies that have been done in the Asia Pacific region, as a broad understanding of the scope and severity of this group of diseases would enable rheumatologists and physicians in this part of the world to better manage their patients. The majority of genetic studies have focused on the associations of HLA-B27 with ankylosing spondylitis (AS) and SpA, while a few studies examined the associations of the CARD, IL-1, LMP2, TAP and TGF with AS. There are a handful of studies on the immunological responses to bacteria and cytokine levels in AS. The onset and clinical features of SpA have been reported from most countries in the region, but no data on patient outcomes, using current measurement tools such as the Bath Ankylosing Spondylitis Disease Activity index (BASDAI), is available. Validation of these instruments of measurement as well as classification criteria in different ethnic populations is necessary where no prior data exist. Future studies will likely be focused on better clinical characterisation of patient cohorts, particularly with regard to the use of currently used measurement tools for disease activity and spinal function and mobility, and the identification of the need for biologic therapy in each country.en
dc.language.isoenen
dc.publisherAcademy of Medicine, Singapore; 1999en
dc.subjectArthritis/epidemiology/genetics/immunology/therapyen
dc.subjectAsian Continental Ancestry Groupen
dc.subjectGenetic Predisposition to Diseaseen
dc.subjectHLA-B27 Antigen/geneticsen
dc.subjectHumansen
dc.subjectSensitivity and Specificityen
dc.subject*Spinal Diseases/epidemiology/genetics/immunology/therapyen
dc.subjectSpondylitis, Ankylosing/genetics/immunologyen
dc.subjectTransforming Growth Factor beta1/immunologyen
dc.titleSeronegative spondyloarthropathy--studies from the Asia Pacific regionen
dc.typeArticleen
dc.contributor.AlternativeAuthor송영욱-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse